Please provide your email address to receive an email when new articles are posted on . Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later ...

In stage N0-1 nasopharyngeal cancer, elective upper-neck irradiation provides outcomes on par with whole-neck irradiation and with significantly lower rates of long-term toxicity, according to ...

Researchers are continuing to study nasopharyngeal carcinoma (NPC) to understand how it develops and what it responds to. Their goal is to provide better outcomes and possible prevention. NPC is a ...

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

The study included patients aged 18–65 years with untreated, nonkeratinizing, stage T1-4 N2-3 M0 nasopharyngeal carcinoma who were treated in a randomized trial at four cancer centers in China. Nearly ...

Please provide your email address to receive an email when new articles are posted on . Researchers found nearly identical 3-year PFS data among the two cohorts. Grade 3 and 4 short-term toxic effects ...

Hypoxic Gene Expression Signature as a Predictor of Recurrence and Mortality in Early-Stage Non–Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy A study of 1,040 patients with ...

Molecular profiling of over 1,000 nasopharyngeal cancer (NPC) patients’ tumours reveals distinct differences in tumour microenvironment of locoregionally advanced NPC, supporting the use of ...

The FDA approved a new PD-1 inhibitor, toripalimab (Loqtorzi), for treating adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), representing the first drug specifically approved for ...

DelveInsight's, “Nasopharyngeal Cancer Pipeline Insight” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape. It covers the ...